PHARMADRUG INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.03 CAD | 0.00% |
|
0.00% | -45.45% |
| Sales 2021 | 0.49 0.68 39.44 | Sales 2022 | - | Capitalization | 5.33M 7.28M 425M |
|---|---|---|---|---|---|
| Net income 2021 | -5M -6.83M -398M | Net income 2022 | -8M -10.92M -637M | EV / Sales 2021 | 23,231,869 x |
| Net cash position 2021 | 429K 586K 34.18M | Net Debt 2022 | 1.09M 1.49M 87.12M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.06
x | P/E ratio 2022 |
-0.59
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.12% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -14.29% | ||
| 1 month | -14.29% | ||
| 3 months | -25.00% | ||
| 6 months | -33.33% | ||
| Current year | -45.45% |
1 week
0.03
0.04
1 month
0.030.04
Current year
0.030.08
1 year
0.030.08
3 years
0.030.74
5 years
0.031.82
10 years
0.034.55
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Steen
CEO | Chief Executive Officer | - | 05/09/23 |
Paul van Slyke
CTO | Chief Tech/Sci/R&D Officer | - | 12/05/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul McClory
BRD | Director/Board Member | 80 | 19/12/16 |
Al Quong
BRD | Director/Board Member | 58 | 30/05/19 |
David Kideckel
CHM | Chairman | - | 29/08/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.03 | 0.00% | 106 817 |
| 26/04/24 | 0.03 | -14.29% | 20,642 |
| 24/04/24 | 0.035 | +16.67% | 2,000 |
| 23/04/24 | 0.03 | 0.00% | 26,288 |
| 22/04/24 | 0.03 | -14.29% | 415,185 |
Delayed Quote Canadian Securities Exchange, April 29, 2024 at 03:09 pm
More quotes
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Companyâs subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -45.45% | 2.29M | |
| +16.31% | 71.39B | |
| +1.79% | 25.1B | |
| -1.22% | 8.59B | |
| +7.95% | 8.19B | |
| -20.96% | 7.91B | |
| +15.26% | 4.31B | |
| -3.38% | 3.93B | |
| -3.02% | 3.86B | |
| +21.10% | 3.64B |
- Stock Market
- Equities
- PHRX Stock
